{"id":"therapeutic-entecavir","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Headache","drugRate":"14%","severity":"Mild"},{"effect":"Fatigue","drugRate":"13%","severity":"Mild"},{"effect":"Dizziness","drugRate":"9%","severity":"Mild"}],"contraindications":["Hypersensitivity to entecavir or any component of the formulation"],"specialPopulations":{"Lactation":"Not recommended due to potential risk to the infant","Pregnancy":"Category C: Risk cannot be ruled out","Renal Impairment":"Dosage adjustment required based on creatinine clearance"}},"trials":[],"_chembl":null,"aliases":["Baraclude"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-04-17","unitCost":"$0.0226/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$8","description":"THERAPEUTIC 3% DANDRUFF SHMP","retrievedDate":"2026-04-07"}],"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Entecavir is an antiviral medication primarily used for the treatment of chronic hepatitis B. Developed and marketed by Bristol Myers Squibb, it is not associated with Taipei Veterans General Hospital, Taiwan. The drug works by inhibiting the replication of the hepatitis B virus. Despite its efficacy, entecavir has no FDA-approved label from Taipei Veterans General Hospital. Common side effects include headache, fatigue, and dizziness. The drug is generally well-tolerated but requires careful monitoring in patients with renal impairment.","ecosystem":[],"mechanism":{"target":"HBV DNA polymerase","novelty":"Entecavir was one of the first nucleoside analogs to show high specificity and potency against HBV.","modality":"Small molecule","drugClass":"Nucleoside analog reverse transcriptase inhibitor (NRTI)","explanation":"Entecavir interferes with the viral DNA synthesis process by competing with the natural substrate deoxyguanosine triphosphate (dGTP) and terminating the growing DNA chain.","oneSentence":"Entecavir is a guanosine nucleoside analog that selectively inhibits the replication of hepatitis B virus (HBV) DNA polymerase.","technicalDetail":"It specifically targets the reverse transcriptase activity of the HBV DNA polymerase, leading to chain termination and inhibition of viral replication."},"_scrapedAt":"2026-03-28T00:12:21.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"Not available from Taipei Veterans General Hospital","launchDate":"Not available from Taipei Veterans General Hospital","annualCostUS":"Not available from Taipei Veterans General Hospital","currentRevenue":"Not available from Taipei Veterans General Hospital","patientPopulation":"Not available from Taipei Veterans General Hospital","peakSalesEstimate":"Not available from Taipei Veterans General Hospital"},"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":["Chronic hepatitis B"],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07493109","phase":"PHASE3","title":"Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-05-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":200},{"nctId":"NCT07459426","phase":"","title":"Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","status":"NOT_YET_RECRUITING","sponsor":"Yaşar Bayındır, MD","startDate":"2026-03-15","conditions":"Hepatitis B, Chronic","enrollment":700},{"nctId":"NCT04431245","phase":"","title":"Stopping Antiviral Treatment in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-06-01","conditions":"Chronic Hepatitis b","enrollment":54},{"nctId":"NCT05763576","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2023-04-28","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT07345624","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":80},{"nctId":"NCT07345611","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":60},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02065336","phase":"PHASE2","title":"A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2014-03","conditions":"Hepatitis B, Chronic","enrollment":58},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT07253220","phase":"NA","title":"TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-01","conditions":"Hepatitis B, Hepatocellular Carcinoma (HCC)","enrollment":120},{"nctId":"NCT07189377","phase":"PHASE4","title":"Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-09-24","conditions":"Hepatitis B Virus (HBV), Lung Transplant Recipient","enrollment":20},{"nctId":"NCT07145268","phase":"PHASE2","title":"Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-09-01","conditions":"Liver Fibroses, HBV (Hepatitis B Virus)","enrollment":44},{"nctId":"NCT07120750","phase":"","title":"Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-09-01","conditions":"Hepatocellular Carcinoma (HCC), Chronic Hepatitis B","enrollment":332},{"nctId":"NCT07095855","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2025-08","conditions":"Chronic Hepatitis B","enrollment":1300},{"nctId":"NCT06990776","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects","status":"WITHDRAWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-07-09","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT07079150","phase":"","title":"Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study","status":"RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2025-01-01","conditions":"Hepatitis B, Chronic (CHB), Hepatitis B, Hepatitis B Virus (HBV)","enrollment":1500},{"nctId":"NCT04942886","phase":"NA","title":"Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation","status":"ENROLLING_BY_INVITATION","sponsor":"Seoul St. Mary's Hospital","startDate":"2021-08-21","conditions":"Hepatitis B Reactivation, Hematopoietic Stem Cell Transplantation, Antiviral Drug","enrollment":226},{"nctId":"NCT04102176","phase":"NA","title":"Halting Nucleoside Analogues in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seng Gee Lim","startDate":"2019-01-29","conditions":"Chronic Hepatitis B","enrollment":120},{"nctId":"NCT04638439","phase":"PHASE1","title":"The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2022-08-17","conditions":"Chronic Hepatitis B Infection, Chronic Hepatitis D Infection","enrollment":20},{"nctId":"NCT05550519","phase":"EARLY_PHASE1","title":"A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment","status":"WITHDRAWN","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2022-10-31","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT05905172","phase":"PHASE3","title":"Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2023-08-12","conditions":"Liver Fibrosis","enrollment":248},{"nctId":"NCT05123599","phase":"PHASE1","title":"A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-06","conditions":"Hepatitis B, Chronic","enrollment":24},{"nctId":"NCT02496897","phase":"PHASE1","title":"Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2015-07","conditions":"Hepatitis B","enrollment":61},{"nctId":"NCT04585789","phase":"PHASE2","title":"A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-11","conditions":"Hepatitis B","enrollment":24},{"nctId":"NCT05182463","phase":"PHASE4","title":"Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-01-08","conditions":"Hepatitis B, Chronic","enrollment":5000},{"nctId":"NCT04535544","phase":"PHASE2","title":"A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-17","conditions":"Hepatitis D, Chronic","enrollment":52},{"nctId":"NCT05275023","phase":"PHASE2","title":"An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-30","conditions":"Hepatitis B, Chronic","enrollment":37},{"nctId":"NCT04294498","phase":"PHASE2","title":"Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-11-02","conditions":"Advanced Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT06000657","phase":"PHASE4","title":"Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-08-28","conditions":"Hepatitis B, Chronic","enrollment":196},{"nctId":"NCT04129554","phase":"PHASE2","title":"A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2019-11-06","conditions":"Hepatitis B, Chronic","enrollment":130},{"nctId":"NCT03982186","phase":"PHASE2","title":"A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2019-08-01","conditions":"Hepatitis B, Chronic","enrollment":471},{"nctId":"NCT05423106","phase":"PHASE1","title":"A Single and Multiple Ascending Dose Study of JNJ-64457744","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-04","conditions":"Healthy, Hepatitis B, Chronic","enrollment":60},{"nctId":"NCT03933384","phase":"PHASE4","title":"Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2019-08-19","conditions":"Hepatitis B, Viral Hepatitis","enrollment":140},{"nctId":"NCT05583006","phase":"","title":"Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2023-11-06","conditions":"Patient Satisfaction, Drug Adherence, Efficacy, Self","enrollment":60},{"nctId":"NCT05115942","phase":"PHASE3","title":"Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.","status":"COMPLETED","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2021-12-30","conditions":"Liver Fibrosis","enrollment":248},{"nctId":"NCT03920618","phase":"NA","title":"Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-02-21","conditions":"Hepatitis B, Acute-On-Chronic Liver Failure","enrollment":150},{"nctId":"NCT02883647","phase":"","title":"Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2014-01-01","conditions":"Chronic Hepatitis b","enrollment":100},{"nctId":"NCT06150014","phase":"PHASE1, PHASE2","title":"A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12-07","conditions":"Chronic Hepatitis b","enrollment":88},{"nctId":"NCT06535048","phase":"","title":"Impact of Fatty Liver on Hepatitis B Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Second People's Hospital","startDate":"2015-01-01","conditions":"Fatty Liver Disease, Chronic Hepatitis B, Antiviral Treatment","enrollment":500},{"nctId":"NCT04667104","phase":"PHASE2","title":"A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hepatitis B, Chronic","enrollment":48},{"nctId":"NCT04147208","phase":"PHASE2","title":"Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2019-02-28","conditions":"Chronic HBV Infection","enrollment":250},{"nctId":"NCT03887702","phase":"PHASE3","title":"Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2020-01-17","conditions":"Hepatitis B Infection, Malignant Solid Neoplasm","enrollment":4},{"nctId":"NCT05453435","phase":"PHASE2","title":"Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-07-15","conditions":"Resolved Hepatitis B, CD20 Positive B-cell Lymphoma","enrollment":84},{"nctId":"NCT06323681","phase":"NA","title":"Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study）","status":"RECRUITING","sponsor":"Qing XIe","startDate":"2024-02-04","conditions":"Chronic Hepatitis b","enrollment":2016},{"nctId":"NCT05005507","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-03","conditions":"Hepatitis B, Chronic","enrollment":1},{"nctId":"NCT04820686","phase":"PHASE2","title":"A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2021-05-07","conditions":"Chronic Hepatitis B","enrollment":65},{"nctId":"NCT03905655","phase":"PHASE2","title":"Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2019-10-22","conditions":"Chronic Hepatitis B","enrollment":51},{"nctId":"NCT05755776","phase":"","title":"The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2023-03-01","conditions":"Chronic Hepatitis B","enrollment":204},{"nctId":"NCT05937178","phase":"","title":"Real-world Study Optimizing Nucleotide-analogues","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2023-01-31","conditions":"Hepatitis B, Chronic","enrollment":20000},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":"Hepatitis D","enrollment":80},{"nctId":"NCT05808335","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)","status":"UNKNOWN","sponsor":"ImmuneMed, Inc.","startDate":"2022-01-11","conditions":"Chronic Hepatitis B","enrollment":32},{"nctId":"NCT05484466","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB","status":"UNKNOWN","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2022-11-11","conditions":"Hepatitis B, Chronic","enrollment":90},{"nctId":"NCT03771677","phase":"NA","title":"To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-01","conditions":"Hepatitis B","enrollment":400},{"nctId":"NCT03780543","phase":"PHASE2","title":"A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2018-12-20","conditions":"Chronic Hepatitis B","enrollment":92},{"nctId":"NCT05792761","phase":"NA","title":"A Study on Antiviral Treatment of Chronic Hepatitis B in Children","status":"UNKNOWN","sponsor":"Fang Wang","startDate":"2021-05-06","conditions":"Chronic HBV Infection","enrollment":1900},{"nctId":"NCT05793268","phase":"NA","title":"Finite Versus Continuous Nucleos(t)Ide Analogues for Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"E-DA Hospital","startDate":"2022-12-20","conditions":"Chronic Hepatitis b","enrollment":360},{"nctId":"NCT04864366","phase":"","title":"Efficacy and Safety of TAF for 48 Weeks in HBeAg Positive CHB Patients","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-04-30","conditions":"Chronic Hepatitis B","enrollment":150},{"nctId":"NCT05721300","phase":"NA","title":"Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer","status":"UNKNOWN","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2023-02-10","conditions":"Hepatocellular Carcinoma, Chronic Hepatitis B","enrollment":2215},{"nctId":"NCT03640728","phase":"","title":"The Efficacy and Safety of Nucleos(t)Ide Analogues in the Treatment of HBV-related Acute-on-chronic Liver Failure","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2019-01-25","conditions":"Hepatitis B, Virus Diseases, Liver Failure","enrollment":200},{"nctId":"NCT05423834","phase":"","title":"Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-09-01","conditions":"Chronic Hepatitis B","enrollment":1800},{"nctId":"NCT05494528","phase":"NA","title":"Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2021-05-04","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT05661786","phase":"","title":"Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-12","conditions":"Chronic Hepatitis b","enrollment":4500},{"nctId":"NCT03736265","phase":"NA","title":"Carvedilol for Prevention of Esophageal Varices Progression","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2017-10-09","conditions":"Cirrhosis, Liver, Portal Hypertension","enrollment":240},{"nctId":"NCT03361956","phase":"PHASE2","title":"An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2018-02-13","conditions":"Hepatitis B","enrollment":232},{"nctId":"NCT00704106","phase":"","title":"Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders","status":"COMPLETED","sponsor":"Pacific Health Foundation","startDate":"2008-05","conditions":"Hepatitis B","enrollment":60},{"nctId":"NCT04454567","phase":"PHASE2","title":"A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2020-11-11","conditions":"Chronic Hepatitis B","enrollment":2},{"nctId":"NCT05256823","phase":"PHASE2","title":"Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues on the Hepatitis B Surface Antigen of Virally Suppressed Subjects With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Lai Wei","startDate":"2022-02-24","conditions":"To Evaluate the Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues in Nucleos(t)Ide-treated Patients With Chronic Hepatitis B","enrollment":47},{"nctId":"NCT05466565","phase":"","title":"Antiviral Therapy for Patients With Liver Cancer After Surgery","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2021-12-01","conditions":"Hepatocellular Carcinoma","enrollment":360},{"nctId":"NCT05453448","phase":"NA","title":"The Renal Safety of Tenofovir Alafenamide in HBV-related Acute-on-chronic Liver Failure: Real-World Study","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-05-01","conditions":"Antiviral Drugs","enrollment":272},{"nctId":"NCT02499562","phase":"PHASE2","title":"A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis","status":"COMPLETED","sponsor":"Shanghai Genomics, Inc.","startDate":"2015-06-25","conditions":"Hepatitis B, Chronic","enrollment":168},{"nctId":"NCT05406089","phase":"","title":"Effects of Antiviral Therapy on Patients With HBV-related HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2016-01-01","conditions":"Hepatocellular Carcinoma, Hepatitis B Virus, Survival","enrollment":494},{"nctId":"NCT05416008","phase":"","title":"The Relationship Between Long-term Oral Anti Hepatitis B Nucleoside Analogs and Hepatic Steatosis","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2021-07-01","conditions":"Hepatic Steatosis","enrollment":150},{"nctId":"NCT02862548","phase":"PHASE2","title":"Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-09-16","conditions":"Chronic Hepatitis B","enrollment":51},{"nctId":"NCT01369199","phase":"PHASE3","title":"Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B","status":"TERMINATED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-05","conditions":"Hepatitis B","enrollment":28},{"nctId":"NCT04032860","phase":"PHASE4","title":"RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2017-07-01","conditions":"HCC, HBV Coinfection","enrollment":104},{"nctId":"NCT04199819","phase":"NA","title":"Detecting Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-01-01","conditions":"Occult Hepatitis B, Liver Transplant; Complications","enrollment":100},{"nctId":"NCT05382351","phase":"PHASE2","title":"Antiviral Therapy for Patients With Chronic Hepatitis B Infection","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-05-10","conditions":"Chronic Hepatitis B Virus Infection","enrollment":238},{"nctId":"NCT03164889","phase":"NA","title":"Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients","status":"TERMINATED","sponsor":"Beijing 302 Hospital","startDate":"2017-01","conditions":"Hepatitis B, Chronic","enrollment":80},{"nctId":"NCT04182321","phase":"NA","title":"Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Fu-Sheng Wang","startDate":"2020-03-13","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT03491553","phase":"PHASE2","title":"Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-04-06","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT04724785","phase":"","title":"Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2020-12-01","conditions":"Sustained Virologic Response, Hepatitis B, Chronic","enrollment":10000},{"nctId":"NCT04886336","phase":"","title":"The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-06-04","conditions":"HBV","enrollment":250},{"nctId":"NCT02849132","phase":"PHASE4","title":"Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2016-01","conditions":"Hepatitis B, Liver Cirrhosis","enrollment":800},{"nctId":"NCT03366571","phase":"","title":"Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2016-01","conditions":"Chronic Hepatitis B","enrollment":600},{"nctId":"NCT02582333","phase":"","title":"Clinical Course Study in Chronic Hepatitis B After Nucleos(t)Ide Analogue Therapy","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2015-10-01","conditions":"Virological Breakthrough, Prognosis","enrollment":347},{"nctId":"NCT03576066","phase":"PHASE2","title":"A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2018-06-11","conditions":"Chronic Hepatitis B","enrollment":73},{"nctId":"NCT04189276","phase":"PHASE2","title":"Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Tasly Tianjin Biopharmaceutical Co., Ltd.","startDate":"2019-12-10","conditions":"Hepatitis B Virus (HBV)","enrollment":100},{"nctId":"NCT03577171","phase":"PHASE2","title":"A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2018-06-19","conditions":"Chronic Hepatitis B","enrollment":25},{"nctId":"NCT01935635","phase":"PHASE1, PHASE2","title":"A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB","status":"COMPLETED","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-01","conditions":"Chronic Hepatitis B","enrollment":400},{"nctId":"NCT04501224","phase":"NA","title":"The Efficacy and Safety of TAF vs Other NAs in Patients With LVL","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-08-03","conditions":"Chronic Hepatitis b, Cirrhosis Due to Hepatitis B","enrollment":200},{"nctId":"NCT04133259","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Henlix, Inc","startDate":"2019-12-31","conditions":"Hepatitis B, Chronic","enrollment":44},{"nctId":"NCT04539119","phase":"PHASE3","title":"Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-07-03","conditions":"B-cell Lymphoma, HBV","enrollment":120},{"nctId":"NCT03258710","phase":"PHASE4","title":"A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-02","conditions":"Hepatitis B, Chronic","enrollment":75},{"nctId":"NCT04405011","phase":"NA","title":"NUC in Preventing HBV Reactivation in HCV/HBV Co-infected Patients Receiving DAA for CHC","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2018-08-01","conditions":"HBV/HCV Co-infection","enrollment":60},{"nctId":"NCT04392700","phase":"PHASE3","title":"A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-07-25","conditions":"Hepatocellular Carcinoma Recurrent","enrollment":706},{"nctId":"NCT04069858","phase":"PHASE4","title":"Maintaining Antiviral Efficacy After Switching to Generic Entecavir 1 mg for Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Korea University","startDate":"2016-12-01","conditions":"Chronic Hepatitis B","enrollment":40},{"nctId":"NCT02945956","phase":"PHASE4","title":"Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":2386,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Therapeutic entecavir","genericName":"Therapeutic entecavir","companyName":"Taipei Veterans General Hospital, Taiwan","companyId":"taipei-veterans-general-hospital-taiwan","modality":"Small molecule","firstApprovalDate":"Not available from Taipei Veterans General Hospital","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}